Antibacterial Nanoparticles Therapeutic (ANT) Study
Closed Pre-Solicitation Posted
This opportunity was awarded. See the award notice from , or the latest special notice from .
- Solicitation number
- PANDHA-26-P-0000_036893
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541713 Research and Development in Nanotechnology
- Place of performance
- Silver Spring, Maryland 20910, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency, on behalf of the Walter Reed Army Institute of Research (WRAIR), is seeking research and development services to conduct the Antibacterial Nanoparticles Therapeutic (ANT) Study, which focuses on testing innovative phage-mimicking nanoparticles (PhANPs) against multi-drug resistant Pseudomonas aeruginosa infections in military personnel. The contractor must provide non-personal R&D effort, including qualified research personnel, appropriate laboratory facilities, and all necessary laboratory and research-related materials and supplies. Key contract requirements include production of nanoparticle batches across three sequential milestones over 36 months, with comprehensive quality control documentation and effectiveness testing against reference bacterial strains. The evaluation criteria emphasize technical capabilities in nanoparticle synthesis and characterization, with particular focus on the contractor's ability to meet strict QC standards and milestone deliverables. The Request for Information response deadline is 10:00 AM ET on April 1, 2026, with responses to be submitted electronically to Ms. Linda Hinson (linda.t.hinson.civ@health.mil) and Mr. Sharew Hailu (sharew.hailu.civ@health.mil).
This procurement does not utilize any set-aside designations. The University of Notre Dame is identified as the patent owner and collaborative partner of the PhANPs technology (US Patent 12161725-B2), indicating potential partnership involvement. No specific award value or budget range is disclosed in this pre-solicitation notice. The 36-month contract spans three milestones: Milestone One (Months 0-9) requires 17 batches totaling 500 mL of nanoparticle stock for biofilm testing; Milestone Two (Months 10-18) requires 3 batches totaling 75 mL for wax-worm infection models; and Milestone Three (Months 19-36) requires 20 batches totaling 570 mL for animal work including mice and swine models. The applicable NAICS code is 541713 (Research and Development in Nanotechnology), and responses should not exceed 3 pages formatted in 12-point font.
Notice text
The BDB seeks to conduct a study to test innovative antibacterial nanoparticles with phage-mimicking properties (PhANPs) against combat relevant multi-drug resistant (MDR) strains of Pseudomonas (P.) aeruginosa, bacterial pathogen to cause hard to treat and even deadly infections in service members after battlefield injuries. There is a need to bring novel therapeutics to the military health care to treat MDR P. aeruginosa. The collaborative partner of this study is the University of Notre Dame, the patent owner of a unique technology (phage-mimicking nanoparticles) that provides life-saving therapeutics for service members and civilians. This technology was awarded a patent in 2024 - US-12161725-B2. Government anticipates that the collaborative efforts will contribute to Food and Drug Administration (FDA) approval of this innovative therapy, leading to reduced morbidity and mortality rates, enhanced operational readiness, advanced combat medicine, and substantial contributions to broader biosecurity initiatives and civilian health improvements.
The contractor shall provide non-personal Research and Development effort. This includes qualified research personnel, appropriate laboratory facilities, and all necessary laboratory and research related materials and supplies.
Files
| File | Type | Posted |
|---|---|---|
| A02. Request for Information PANDHA-26-P-0000 036893 ANT Study.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| Antibacterial Nanoparticles Therapeutic (ANT) Study | Award Notice | |
| Antibacterial Nanoparticles Therapeutic (ANT) Study | Special Notice | |
| This notice | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination | — | No set-aside | |
| 2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases | National Institute of Allergy and Infectious Diseases | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity